Norway Lung Cancer Diagnostics Market to 2032
Overview
The Norway Lung Cancer Diagnostics Market is expected to reach a 23.00 USD Billion by 2032 and is projected to grow at a CAGR of 9.66% from 2025 to 2032.
Revenue, 2024 (USD Billion)
13.13
Forecast, 2032 (USD Billion)
23.00
CAGR, 2024 - 2032
9.66%
Report Coverage
Norway
Norway Lung Cancer Diagnostics Market 2018-2032 USD Billion
Norway Lung Cancer Diagnostics Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 13.13 USD Billion
- Projected Market Size (2032): 23.00 USD Billion
- CAGR (2025-2032): 9.66%
Key Findings of Norway Lung Cancer Diagnostics Market
- The Norway Lung Cancer Diagnostics Market was valued at 13.13 USD Billion in 2024.
- The Norway Lung Cancer Diagnostics Market is likely to grow at a CAGR of 9.66% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Non-Small Cell Lung Cancer in Cancer Segment accounted for the largest share of the market with a revenue of 10.29 USD Billion
- The fastest growing segment Hospital in End User Segment grew Fastest with a CAGR of 11.57% during the forecast period from 2024 to 2032.
Norway Lung Cancer Diagnostics Market Scope
Norway Lung Cancer Diagnostics Market Segmentation & Scope
Distribution Channel
- Retail Sales
- Direct Tender
End User
- Others
- Cancer Research Institutes
- Diagnostic Imaging Centers
- Independent Diagnostic Laboratories
- Associated Labs
- Hospital
Cancer
- Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
Test
- Others
- Blood Test
- Biopsy
- Biomarkers Test
- Imaging Test
Product
- Consumables & Accessories
- Instruments
Norway Lung Cancer Diagnostics Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 13.13 USD Billion |
| Market Value in 2032 | 23.00 USD Billion |
| CAGR (2025-2032) | 9.66% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Distribution Channel,End User,Cancer,Test,Product |
Regional Insights:
-
Leading Market (2024-2032): Norway, leading in terms of revenue 13.13 USD Billion in 2024
- Key Country: Norway, leading in terms of revenue with value of 13.13 USD Billion in 2024.
Segments and Scope
-
Norway Lung Cancer Diagnostics Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in Norway Lung Cancer Diagnostics Market to 2032 with a revenue of 7.69 USD Billion in the year 2024.
- Direct Tender is the Fastest growing segment in Norway Lung Cancer Diagnostics Market to 2032 with a Growth rate of 10.74 % in forecast period 2025-2032.
-
Norway Lung Cancer Diagnostics Market to 2032, By End User
- Hospital is the largest segment in Norway Lung Cancer Diagnostics Market to 2032 with a revenue of 4.09 USD Billion in the year 2024.
- Hospital is the Fastest growing segment in Norway Lung Cancer Diagnostics Market to 2032 with a Growth rate of 11.57 % in forecast period 2025-2032.
-
Norway Lung Cancer Diagnostics Market to 2032, By Cancer
- Non-Small Cell Lung Cancer is the largest segment in Norway Lung Cancer Diagnostics Market to 2032 with a revenue of 10.29 USD Billion in the year 2024.
- Non-Small Cell Lung Cancer is the Fastest growing segment in Norway Lung Cancer Diagnostics Market to 2032 with a Growth rate of 9.88 % in forecast period 2025-2032.
-
Norway Lung Cancer Diagnostics Market to 2032, By Test
- Imaging Test is the largest segment in Norway Lung Cancer Diagnostics Market to 2032 with a revenue of 6.88 USD Billion in the year 2024.
- Imaging Test is the Fastest growing segment in Norway Lung Cancer Diagnostics Market to 2032 with a Growth rate of 10.61 % in forecast period 2025-2032.
-
Norway Lung Cancer Diagnostics Market to 2032, By Product
- Instruments is the largest segment in Norway Lung Cancer Diagnostics Market to 2032 with a revenue of 8.66 USD Billion in the year 2024.
- Instruments is the Fastest growing segment in Norway Lung Cancer Diagnostics Market to 2032 with a Growth rate of 10.45 % in forecast period 2025-2032.
Norway Lung Cancer Diagnostics Market Company Share Analysis
| Company Name |
|
||
| Thermo Fisher Scientific Inc. | |||
| Quest Diagnostics Incorporated | |||
| Bio-Rad Laboratories, Inc. | |||
| Abbott | |||
| Guardant Health | |||
Norway Lung Cancer Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Billion
Norway Lung Cancer Diagnostics Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Norway Lung Cancer Diagnostics Market is segmented based on Segmentation Distribution Channel,End User,Cancer,Test,Product.
Norway Lung Cancer Diagnostics Market was valued at USD 13.13(Revenue in USD Billion) in 2021.
Norway Lung Cancer Diagnostics Market is projected to grow at a CAGR of 9.66% during the forecast period of 2024 to 2032.
The Non-Small Cell Lung Cancer segment is expected to dominate the Norway Lung Cancer Diagnostics Market, holding a largest market share of 10.29 USD Billion in 2024
Norway Lung Cancer Diagnostics Market Scope
Norway Lung Cancer Diagnostics Market Segmentation & Scope
Distribution Channel
- Retail Sales
- Direct Tender
End User
- Others
- Cancer Research Institutes
- Diagnostic Imaging Centers
- Independent Diagnostic Laboratories
- Associated Labs
- Hospital
Cancer
- Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
Test
- Others
- Blood Test
- Biopsy
- Biomarkers Test
- Imaging Test
Product
- Consumables & Accessories
- Instruments
Frequently Asked Questions
The Norway Lung Cancer Diagnostics Market is segmented based on Segmentation Distribution Channel,End User,Cancer,Test,Product.
Norway Lung Cancer Diagnostics Market was valued at USD 13.13(Revenue in USD Billion) in 2021.
Norway Lung Cancer Diagnostics Market is projected to grow at a CAGR of 9.66% during the forecast period of 2024 to 2032.
The estimated market value of the Norway Lung Cancer Diagnostics Market for final year is USD 23.00 (USD Billion).
Norway Lung Cancer Diagnostics Market Company Profiling
Frequently Asked Questions
The Norway Lung Cancer Diagnostics Market is segmented based on Segmentation Distribution Channel,End User,Cancer,Test,Product.
Norway Lung Cancer Diagnostics Market was valued at USD 13.13(Revenue in USD Billion) in 2021.
Norway Lung Cancer Diagnostics Market is projected to grow at a CAGR of 9.66% during the forecast period of 2024 to 2032.
The estimated market value of the Norway Lung Cancer Diagnostics Market for final year is USD 23.00 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.